Fufang Huangbo Formula mitigates myeloproliferative neoplasms by activating p53/p21 signaling axis and inhibiting STAT3 and NF-κB signaling pathways
Pharmaceutical Science Advances · 2026-12 · 4 · 100121
DOI: 10.1016/j.pscia.2026.100121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Science Advances, 2026-12. Verfasst von Mingjie Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shandong University, Jinan, Shandong, 250…. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Programme, Natural Science Foundation of Shandong Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shandong University, Jinan, Shandong, 250012, China.
- Key Lab of Chemical Biology (MOE), Shandong University, Jinan, Shandong, 250012, China.
- NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, Shandong University, Jinan, Shandong, 250012, China.
- Department of Pharmacology, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China.
- Research Center for Traditional Chinese Medicine and Clinical Pharmacy, Shandong Provincial Maternal and Child Health Care Hospital, Jinan, Shandong, 250012, China.
- Department of Spine Surgery, Heze Municipal Hospital, 2888 Caozhou Road, Heze, Shandong, 274031, China.
Förderung
- Key Programme
- Natural Science Foundation of Shandong Province
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Liu, M., Li, Y., Qin, C., Wang, L., Guo, M., Wang, Y., Zhou, Q., Shi, Z., Hao, W., Li, Y., & Zhao, B. (2026). Fufang Huangbo Formula mitigates myeloproliferative neoplasms by activating p53/p21 signaling axis and inhibiting STAT3 and NF-κB signaling pathways. Pharmaceutical Science Advances, 4, 100121. https://doi.org/10.1016/j.pscia.2026.100121
Vancouver
Liu M, Li Y, Qin C, Wang L, Guo M, Wang Y, et al. Fufang Huangbo Formula mitigates myeloproliferative neoplasms by activating p53/p21 signaling axis and inhibiting STAT3 and NF-κB signaling pathways. Pharmaceutical Science Advances. 2026;4:100121. doi:10.1016/j.pscia.2026.100121
BibTeX
@article{Liu2026,
author = {Liu, Mingjie and Li, Yanxia and Qin, Chengxue and Wang, Lingling and Guo, Meiqi and Wang, Yi and Zhou, Qian and Shi, Zhida and Hao, Weimin and Li, Yuan and Zhao, Baobing},
title = {Fufang Huangbo Formula mitigates myeloproliferative neoplasms by activating p53/p21 signaling axis and inhibiting STAT3 and NF-κB signaling pathways},
journal = {Pharmaceutical Science Advances},
year = {2026},
volume = {4},
pages = {100121},
doi = {10.1016/j.pscia.2026.100121}
}
EUVIMED